This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
Denali (DNLI) Lags Q3 Earnings Estimates, Pipeline in Focus
by Zacks Equity Research
Denali (DNLI) posts a wider Q3 loss. Collaboration revenues decline year over year.
SNYPositive Net Change BIIBPositive Net Change DNLIPositive Net Change
biotechnology biotechs earnings
Prothena's (PRTA) Q3 Earnings Miss, Revenues Decline Y/Y
by Zacks Equity Research
Prothena (PRTA) incurs a loss in the third quarter while revenues miss estimates.
RHHBYPositive Net Change BMYPositive Net Change NVONegative Net Change PRTAPositive Net Change
biotechnology biotechs
After Golden Cross, Associated Banc-Corp (ASB)'s Technical Outlook is Bright
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
ASBNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology bitcoin blockchain cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Dorian LPG (LPG)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
LPGPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology bitcoin blockchain cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Regeneron (REGN) Q3 Earnings & Sales Beat on Eylea, Dupixent
by Zacks Equity Research
Regeneron (REGN) tops earnings and sales estimates for the third quarter, driven by its lead drug Eylea and profits from the asthma drug, Dupixent. However, earnings decline year over year.
REGNPositive Net Change SNYPositive Net Change RHHBYPositive Net Change BAYRYNegative Net Change
biotechnology biotechs earnings
Hancock Whitney (HWC) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
HWCNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology bitcoin blockchain cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Intercept (ICPT) Q3 Earnings Miss, Sales Beat, View Raised
by Zacks Equity Research
Intercept (ICPT) posts a wider loss in Q3 due to a loss on extinguishment of debt but beats on sales. Management increases annual sales guidance.
DVAXPositive Net Change PBYINegative Net Change ICPTPositive Net Change VKTXPositive Net Change
biotechnology earnings
Exelixis (EXEL) Q3 Earnings & Sales Top, Cabometyx Aids Growth
by Zacks Equity Research
Exelixis (EXEL) tops earnings and sales estimates for the third quarter as demand for its lead drug, Cabometyx, remains strong.
BMYPositive Net Change PFEPositive Net Change MRKPositive Net Change EXELPositive Net Change
biotechnology earnings
Chuy's Holdings (CHUY) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
CHUYPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology bitcoin blockchain cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
The Bank of Princeton (BPRN)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
BPRNPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology bitcoin blockchain cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Amerisafe (AMSF) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
AMSFNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology bitcoin blockchain cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
MainStreet Bank (MNSB) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
MNSBNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology bitcoin blockchain cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Nov Inc. (NOV) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
NOVNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology bitcoin blockchain cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Washington Federal (WAFD) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
WAFDNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology bitcoin blockchain cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Gilead (GILD) Q3 Earnings & Sales Top, Guidance Raised
by Zacks Equity Research
Gilead (GILD) Q3 earnings and sales beat on strong HIV and oncology business. The company also raises its annual guidance.
DVAXPositive Net Change MRKPositive Net Change GILDPositive Net Change PBYINegative Net Change
biotechnology biotechs earnings
Equity Bancshares (EQBK) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
EQBKNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology bitcoin blockchain cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Incyte (INCY) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Incyte's (INCY) third-quarter 2022 earnings are likely to have gained from higher Jakafi sales and incremental sales from newly approved drugs.
INCYPositive Net Change JAZZPositive Net Change ACADNegative Net Change EDITPositive Net Change
biotechnology biotechs
LIMESTONE BANCORP, INC. (LMST) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
LMSTPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology bitcoin blockchain cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Biotech Stock Roundup: BIIB & BMY's Q3 Earnings, TCDA Down on Study Update
by Zacks Equity Research
Earnings updates from BIIB and BMY are the key highlights from the biotech sector during the past week.
REGNPositive Net Change BIIBPositive Net Change BMYPositive Net Change TCDAPositive Net Change
biotechnology biotechs
NexTier Oilfield Solutions (NEX) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology bitcoin blockchain cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Buy Schlumberger (SLB) After Golden Cross?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
SLBNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology bitcoin blockchain cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
A Bear Market Rally or Markets Forming a Solid Base: 5 Picks
by Nalak Das
We have narrowed our search to five large-cap U.S. companies with strong potential for the rest of 2022. These are: IBKR, INCY, WMB, HUBB and LW.
WMBNegative Net Change IBKRNegative Net Change INCYPositive Net Change HUBBNegative Net Change LWPositive Net Change
biotechnology industrial-products oil-energy
Will Eliquis, Opdivo Fuel Bristol-Myers (BMY) Q3 Earnings?
by Zacks Equity Research
Investors are likely to focus on the demand for Eliquis and Opdivo along with an incremental contribution from newer drugs when Bristol-Myers (BMY) reports Q3 results. Operating expenses might have jumped.
BMYPositive Net Change BMRNPositive Net Change ACADNegative Net Change EDITPositive Net Change
biotechnology biotechs pharmaceuticals
Biotech Stock Roundup: NERV, RLMD Down on Updates, MRNA, NVAX's News & More
by Zacks Equity Research
Regulatory and pipeline updates from NERV and RLMD are the key highlights from the biotech sector during the past week.
BIIBPositive Net Change MRNAPositive Net Change NVAXPositive Net Change NERVPositive Net Change RLMDPositive Net Change
biotechnology biotechs
Regeneron (REGN) Drug Gets Positive CHMP View for Cervical Cancer
by Zacks Equity Research
Regeneron (REGN) gets a positive recommendation from CHMP for the label expansion of its oncology drug for treating adult patients with recurrent or metastatic cervical cancer.
REGNPositive Net Change SNYPositive Net Change DVAXPositive Net Change BOLTPositive Net Change
biotechnology pharmaceuticals